<document>

<filing_date>
2020-05-20
</filing_date>

<publication_date>
2020-11-26
</publication_date>

<priority_date>
2019-05-20
</priority_date>

<ipc_classes>
C07K14/705,C07K16/28,G01N33/569,G01N33/68
</ipc_classes>

<assignee>
PANDION THERAPEUTICS INC
</assignee>

<inventors>
MAURER DAVID
EDWARDS LINDSAY
GLANVILLE JACOB
OTIPOBY KEVIN LEWIS
PETTUS CHRISTINA
IVES SARAH
VISWESWARAIAH JYOTHSNA
VINEY JOANNE
HIGGINSON-SCOTT NATHAN
ALIOTO SALVATORE
SCHWIMMER LAUREN
SAMPSON ERIK
</inventors>

<docdb_family_id>
73459465
</docdb_family_id>

<title>
MADCAM TARGETED IMMUNOTOLERANCE
</title>

<abstract>
Methods and compounds for conferring site-specific or local immune privilege, such as targeting to a cell expressing MAdCAM. Disclosed herein are methods and therapeutic compounds that provide site-specific immune privilege. In some embodiments, the therapeutic compound comprises an engineered multi-specific compound, e.g., an engineered bi-specific molecule, e.g., an engineered bi-specific antibody molecule.
</abstract>

<claims>
1. An antibody that binds to MadCAM, wherein the antibody comprises one or more sequence as provided in Table 6 or Table 7.
2. The antibody of claim 1, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
(i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of any of the CDR1 sequences set forth in Table 6 or Table 7; the heavy chain CDR2 has the amino acid sequence of any of the CDR2 sequences set forth in Table 6 or Table 7, and the heavy chain CDR3 has the amino acid sequence of any of the CDR3 sequences set forth in Table 6 or Table 7, or variants of any of the foregoing; and
(ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of any of the CDR1 sequences set forth in Table 6 or Table 7; the light chain CDR2 has the amino acid sequence of any of the CDR2 sequences set forth in Table 6 or Table 7, and the light chain CDR3 has the amino acid sequence of any of the CDR3 sequences set forth in Table 6 or Table 7, or variants of any of the foregoing.
3. The antibody of any one of claims 1-2, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NOs: 90, 359, or 135; the heavy chain CDR2 has the amino acid sequence of SEQ ID NOs: 91, 170, or 381, and the heavy chain CDR3 has the amino acid sequence of SEQ ID NOs: 92, 360, or 382, or variants of any of the foregoing; and
(ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NOs: 93, 361, or 383; the light chain CDR2 has the amino acid sequence of SEQ ID NOs: 87, 362, or 384, and the light chain CDR3 has the amino acid sequence of SEQ ID NOs: 94, 363, or 385, or variants of any of the foregoing. 4. The antibody of any one of claims 1-3, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 90, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 91, and the heavy chain CDR3 has the amino acid sequence of SEQ ID NO: 92, or variants of any of the foregoing; and
(ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO:, 93, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 87, and the light chain CDR3 has the amino acid sequence of SEQ ID NO: 94, or variants of any of the foregoing.
5. The antibody of any one of claims 1-2, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence of SEQ ID NO: 135, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 381, and the heavy chain CDR3 has the amino acid sequence of SEQ ID NO: 382, or variants of any of the foregoing; and
(ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO:, 383, the light chain CDR2 has the amino acid sequence of SEQ ID NO: 384, and the light chain CDR3 has the amino acid sequence of SEQ ID NO: 385, or variants of any of the foregoing.
6. The antibody of any one of claims 1-2, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
i) a heavy chain variable region comprising heavy chain CDR1, CDR2, and CDR3 sequences, wherein the heavy chain CDR1 sequence has the amino acid sequence SEQ ID NO: 359, the heavy chain CDR2 has the amino acid sequence of SEQ ID NO: 170, and the heavy chain CDR3 has the amino acid sequence of SEQ ID NO:360, or variants of any of the foregoing; and (ii) a light chain variable region comprising light chain CDR1, CDR2, and CDR3 sequences, wherein the light chain CDR1 sequence has the amino acid sequence of SEQ ID NO:, 361, the light chain LCDR2 has the amino acid sequence of SEQ ID NO: 362, and the light chain CDR3 has the amino acid sequence of SEQ ID NO: 363, or variants of any of the foregoing.
7. The antibody of any one of the preceding claims, wherein the heavy chain variable region and the light chain variable region are in a scFv format.
8. The antibody of claim 3, wherein the heavy chain variable region and the light variable chain region are in a scFv format.
9. The antibody of claim 4, wherein the heavy chain variable region and the light variable chain region are in a scFv format.
10. The antibody of claim 5, wherein the heavy chain variable region and the light variable chain region are in a scFv format.
11. The antibody of claim 6, wherein the heavy chain variable region and the light variable chain region are in a scFv format.
12. The antibody of any one of claims 7-11, wherein the heavy chain variable region and the light variable chain region are linked with a peptide linker, such as a glycine/serine linker.
13. The antibody of claim 1, or antigen binding fragment thereof, wherein the antibody comprises a VK sequence as shown in Table 7.
14. The antibody of claim 13, wherein the VK sequence comprises a sequence of SEQ ID NOs: 415, 592, or 600.
15. The antibody of claims 1, 13, or 14, or antigen binding fragment thereof, wherein the antibody comprises a VH sequence as shown in Table 7. 16. The antibody of claim 15, wherein the VH sequence comprises a sequence of SEQ ID NOs: 414, 591, or 599
17. The antibody of claim 1, or antigen binding fragment thereof, wherein the antibody comprises a VK sequence as shown in Table 7 and a VH sequence as shown in Table 7.
18. The antibody of claim 17, or antigen binding fragment thereof, wherein the antibody comprises a VK of SEQ ID NO: 415, or a variant thereof, and a VH sequence of SEQ ID NO:
414, or a variant thereof.
19. The antibody of claim 17, or antigen binding fragment thereof, wherein the antibody comprises a VK of SEQ ID NO: 592, or a variant thereof and a VH sequence of SEQ ID NO: 591, or a variant thereof.
20. The antibody of claim 17, or antigen binding fragment thereof, wherein the antibody comprises a VK of SEQ ID NO: 600, or a variant thereof, and a VH sequence of SEQ ID NO:
599. or a variant thereof.
21. The antibody of any of the preceding claims, wherein the antibody is linked or associated with an effector molecule.
22. The antibody of claim 21, wherein the effector molecule is a IL-2 mutein.
23. The antibody of claim 22, wherein the IL-2 mutein comprises one or more mutations of E15Q, H16N, Q22E, D84N, E95Q, Q126E, N29S, Y31S, Y31H, K35R, T37A, K48E, N71R, L53I, L56I, L80I, LI 181, V69A, Q74P, N88D, N88R, C125A or C125S.
24. The antibody of claims 22 or 23, wherein the IL-2 mutein comprises a L53I, L56I, L80I, or LI 181 mutation. 25. The antibody of any one of claims 22-24, wherein the IL-2 mutein comprises a N88D mutation.
26. The antibody of any one of claims 22-25, wherein the IL-2 mutein comprises a E15Q, H16N, Q22E, D84N, E95Q, or Q126E mutation.
27. The antibody of claims 22 or 23, wherein the IL-2 mutein comprises a N29S, Y31S, Y51H, K35R, T37A, K48E, V69A, N71R, Q74P, N88D, N88R, C125A, or C125S mutation.
28. The antibody of any one of claims 22-27, wherein the IL-2 mutein is fused or linked to a Fc peptide.
29. The antibody of claim 28, wherein the Fc peptide comprises a mutation at one or more of positions of L234, L235 and G237 according to the EU numbering system or L247, L248, and G250 according to the Rabat numbering system.
30. The antibody of claim 28, wherein the Fc peptide comprises a L234A mutation, a L235A mutation, and/or a G237A mutation according to the EU numbering system.
31. The antibody of claim 21, wherein the antibody linked to the effector molecule comprises a first polypeptide chain and a second a polypeptide chain that form a targeted effector polypeptide, wherein
the first chain comprises a polypeptide having the formula of:
VH-Hc-Linker-Ci, wherein VH is the heavy chain variable domain of the antibody of any one of claims 1-20; Hc is a heavy chain constant domain, such as a CH1-CH2-CH3 domain (SEQ ID NO: 44), the Linker is a glycine/serine linker, and Ci is the IL-2 mutein fused or linked to a Fc protein, wherein the Fc protein is fused or linked at the N-terminus or the C-terminus of the IL-2 mutein; and
the second chain comprises a polypeptide having the formula of VL-Lc, wherein VL is a light chain variable domain of the antibody of any one of claims 1-, and the Lc domain is a kappa light chain constant domain. 32. A polypeptide having a formula of:
Ab-ConstantDomain-LinkerA-IL2Mutein-LinkerB-FcRegion,
wherein the Ab is a heavy chain variable region of any one of claims 1-20;
the ConstantDomain is an IgG constant domain, such as IgGi constant domain, IgG2 constant domain, IgG3 constant domain, or IgG4;
Linker A is a linker, such as those provided herein including a peptide linker, IL2Mutein is an IL-2 mutein, such as those provided for herein;
Linker B is a peptide linker; and
FcRegion is a Fc region, such as those provided for herein.
33. The polypeptide of claim 32, wherein, the heavy chain variable region is a heavy chain variable region as provided for in Table 7, or any variant thereof.
34. The polypeptide of claim 32, wherein, the heavy chain variable region is a heavy chain variable region of Clone ID: 6, 75, or 79 of Table 7, or any variant thereof.
35. The polypeptide of claim 32, wherein the heavy chain variable comprises the CDRs of the heavy domain of 6, 75, or 79 of Table 7, or any variant thereof.
36. The polypeptide of claim 32, wherein heavy chain variable region comprises a sequence of SEQ ID NO: 414, SEQ ID NO: 591, or SEQ ID NO: 599, or any variant thereof.
37. The polypeptide of claim 32, wherein the heavy chain variable region comprises: a first CDR of SEQ ID NO: 90, a second CDR of SEQ ID NO: 91, and a third
CDR of SEQ ID NO: 92, or any variant thereof;
a first CDR of SEQ ID NO: 359, a second CDR of SEQ ID NO: 170, and a third CDR of SEQ ID NO: 360, or any variant thereof; or
a first CDR of SEQ ID NO: 135, a second CDR of SEQ ID NO: 381, and a third CDR of SEQ ID NO: 382, or any variant thereof. 38. The polypeptide of any one of claims 32-38, wherein LinkerA comprises a sequence of (GGGGS)n or (GGGGA)n, or a mixture thereof, wherein each n is independently 1-10.
39. The polypeptide of claim 32, wherein the IL-2 mutein comprises a sequence of any one of SEQ ID NOs: 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41.
40. The polypeptide of any one of claims 32-39, wherein the IL-2 mutein comprises a T3A mutation.
41. The polypeptide of any one of claims 32-40, wherein Linker B is a linker, such as a peptide linker that comprises a sequence of (GGGGS)n or (GGGGA)n, or a mixture thereof, wherein each n is independently 1-10.
42. The polypeptide of any one of claims 32-41, wherein the LcRegion comprises a peptide of having a sequence of SEQ ID NO: 21 or SEQ ID NO: 28.
43. The polypeptide of any one of claims 32-42, wherein the polypeptide comprises a second polypeptide having a formula of VL-ConstantDomainLight, wherein VL is a light chain variable domain of the antibody of any one of claims 1-20 and the ConstantDomainLight is a IgG light chain constant domain.
44. The polypeptide of claim 43, wherein VL comprises a sequence of SEQ ID NO: 415, SEQ ID NO: 592, or SEQ ID NO: 600, or a VL sequence as provided for in Table 7, or any variant thereof.
45. The polypeptide of claim 43, wherein the VL comprises:
a first CDR of SEQ ID NO: 93, a second CDR of SEQ ID NO: 87, and a third CDR of SEQ ID NO: 94;
a first CDR of SEQ ID NO: 361, a second CDR of SEQ ID NO: 362, and a third CDR of SEQ ID NO: 363; or a first CDR of SEQ ID NO: 383, a second CDR of SEQ ID NO: 384, and a third CDR of SEQ ID NO: 385.
46. The polypeptide of any one of claims 42-45, wherein the ConstantDomainLight comprises a sequence of SEQ ID NO: 45.
47. A polypeptide comprising the formula of IL2Mutein-LinkerA-FcRegion-LinkerB-Ab, wherein:
IL2Mutein is any IL-2 mutein provided for herein;
LinkerA and Linker B are, each, independently, a linker as provided herein;
the FcRegion is Fc peptide, such as provided herein; and
the Ab is a tissue targeting moiety, such as those provided herein.
48. The polypeptide of claim 47, wherein the Ab is an antibody that binds to MAdCAM or another cell surface target as provided herein.
49. The polypeptide of claim 48, wherein the antibody that binds to MAdCAM is an antibody of any one of claims 1-20.
50. The polypeptide of claim 49, wherein the antibody is in a scFV format.
51. The polypeptide of claim 50, wherein the antibody in scFV format is an antibody as provided in Table 6.
52. The polypeptide of claim 49, wherein the antibody that binds to MAdCAM comprises CDRs as set forth in Table 6 or Table 7.
53. The antibody of claim 21, wherein the effector molecule is an antibody that binds to PD-
1.
54. The antibody of claim 53, wherein the antibody that binds to PD-1 is a PD-1 agonist. 55. A polypeptide comprising a MAdCAM targeting moiety that binds to a target cell expressing MAdCAM and an effector binding/modulating moiety,
wherein the MAdCAM targeting moiety is an antibody of any one of claims 1-20, wherein the effector binding/modulating moiety is a IL-2 mutein polypeptide (IL-2 mutein), wherein the IL-2 mutein comprises the sequence of SEQ ID NO: 60, wherein at least one of X1, X2, X3, and X4 is I and the remainder are L or I.
56. The polypeptide of claim 55, wherein the IL-2 mutein binds to a receptor expressed by an immune cell.
57. The polypeptide of claim 55, wherein the compound has the formula from N-terminus to C-terminus:
Rl— Linker Region A— R2 or R3— Linker Region B— R4,
wherein,
Rl, R2, R3, and R4, each independently comprises the effector
binding/modulating moiety, the targeting moiety, or is absent.
58. The polypeptide of claim 57, wherein one or both of Linker Region A and Linker Region B comprises an Fc region.
59. The polypeptide of claim 57, wherein one of Rl and R2 is the IL-mutein and one of Rl and R2 is an anti-MAdCAM antibody of any one of claims 1-20.
60. The polypeptide of claim 57, wherein Rl is the IL-mutein and R2 is an anti-MAdCAM antibody of any one of claims 1-20.
61. The polypeptide of claim 57, wherein one of Rl is anti-MAdCAM antibody of any one of claims 1-20 and one R2 is an antiPD- 1 antibody.
62. The polypeptide of claim 57, wherein one of R3 and R4 is the IL-2 mutein and one of R3 and R4 is an anti-MAdCAM antibody of any one of claims 1-20. 63. The polypeptide of claim 57, wherein R3 is the IL-2 mutein and R4 is an anti-MAdCAM antibody.
64. The polypeptide of claim 57, wherein R3 is an anti-MAdCAM antibody of any one of claims 1-20 and one R4 is the IL-2 mutein.
65. The polypeptide of any of claims 57-64, wherein the linker is absent.
66. The polypeptide of any of claims 57-64, wherein the linker is a Fc region.
67. The polypeptide of any of claims 57-64, wherein the linker is a glycine/serine linker.
68. The polypeptide of claim 57, wherein the linker is GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 22), GGGGSGGGGSGGGGS (SEQ ID NO: 30), GGGGSGGGGS (SEQ ID NO: 619), or GGGGS (SEQ ID NO: 23).
69. The polypeptide of claim 55, wherein the IL-2 mutein comprises a IL-2 sequence of SEQ ID NO: 6, wherein peptide comprises a mutation at a position that corresponds to position 53, 56, 80, or 118 of SEQ ID NO: 6.
70. The polypeptide of any one of claims 55-69, wherein the IL-2 mutein comprises a IL-2 sequence of SEQ ID NO: 6, wherein peptide comprises a mutation at a position that corresponds to position 53, 56, 80, or 118 of SEQ ID NO: 6.
71. The polypeptide of claim 69, wherein the mutation is a L to I mutation at position 53, 56, 80, or 118.
72. The polypeptide of claim 70, wherein the mutation is a L to I mutation at position 53, 56, 80, or 118. 73. The polypeptide of claim 55, 69, or 72, further comprising a mutation at one or more positions of 29, 31, 35, 37, 48, 69, 71, 74, 88, and 125 in SEQ ID NO: 6.
74. The polypeptide of any one of claims 55-73, wherein the mutein further comprises a mutation at one or more of positions E15, H16, Q22, D84, E95, or Q126 or 1, 2, 3, 4, 5, or each of positions E15, H16, Q22, D84, E95, or Q126 is wild-type.
75. The polypeptide of any one of claims 55-74, wherein the mutation in the mutein is one or more of E15Q, H16N, Q22E, D84N, E95Q, or Q126E.
76. The polypeptide of any one of claims 55-75, wherein the mutein comprises a V69A mutation.
77. The polypeptide of any one of claims 55-76, wherein the mutein comprises a Q74P mutation.
78. The polypeptide of any one of claims 55-77, wherein the mutein comprises a N88D or a N88R mutation.
79. The polypeptide of any one of claims 55-78, wherein the mutein comprises a C 125 A or C125S mutation.
80. The polypeptide of any one of claims 55-79, wherein the IL-2 mutein is fused or linked to a Fc peptide, such as a protein comprising a sequence of SEQ ID NO: 59.
81. The polypeptide of claim 80, wherein the Fc peptide comprises a mutation at one or more of positions of L234, L247, L235, L248, G237, and G250.
82. The polypeptide of claim 80, wherein the mutation is L to A or G to A mutation. 83. The polypeptide of claim 80, wherein the Fc peptide comprises L247A, L248A, and G250A mutations.
84. The polypeptide of claim 80, wherein the Fc peptide comprises a L234A mutation, a L235A mutation, and/or a G237A mutation.
85. The polypeptide of claim 55, wherein the polypeptide comprises a first chain and a second chain that form the polypeptide, wherein
the first chain comprises:
VH-Hc-Linker-Ci, wherein VH is a variable heavy domain that binds to MAdCAM expressed on a cell with a VL domain of the second chain; Hc is a heavy chain of antibody comprising CH1-CH2-CH3 domain, the Linker is a glycine/serine linker, and Ci is a IL-2 mutein fused to a Fc protein in either the N-terminal or C-terminal orientation; and
the second chain comprises:
VL-LC, wherein VL is a variable light chain domain that binds to MAdCAM expressed on a cell with the VH domain of the first chain, and the Lc domain is a light chain CK domain, Wherein VL and VH comprises a sequence of an antibody of any one of claims 1-20.
86. The polypeptide of claim 85, wherein the IL-2 mutein comprises a mutation at a position that corresponds to position 53, 56, 80, or 118 of SEQ ID NO: 6.
87. The polypeptide of claim 86, wherein the mutation is a L to I mutation at position 53, 56, 80, or 118.
88. The polypeptide of claim 85, wherein the mutein further comprises a mutation at a position that corresponds to position 69, 75, 88, or 125, or any combination thereof.
89. The polypeptide of claim 85, comprises a mutation selected from the group consisting of: at one of L53I, L56I, L80I, and LI 181 and the mutations of V69A, Q74P, N88D or N88R, and optionally C125A or C125S. 90. The polypeptide of claim 89, wherein the IL-2 mutein comprises a L53I mutation.
91. The polypeptide of claim 89, wherein the IL-2 mutein comprises a L56I mutation.
92. The polypeptide of claim 89, wherein the IL-2 mutein comprises a L80I mutation.
93. The polypeptide of claim 89, wherein the IL-2 mutein comprises a LI 181 mutation.
94. The polypeptide of any one of claims 89-93, wherein the IL-2 mutein comprises a T3A mutation.
95. The polypeptide of claim 89 or 94, wherein the IL-2 mutein does not comprises any other mutations.
96. The polypeptide of claim 85, wherein the Fc protein comprises L247A, L248A, and G250A mutations or a L234A mutation, a L235A mutation, and/or a G237A mutation according to RABAT numbering.
97. The polypeptide of claim 85, wherein the Linker comprises a sequence of
GGGGSGGGGSGGGGS (SEQ ID NO: 30) or GGGGS GGGGSGGGGSGGGGS (SEQ ID NO: 22).
98. The polypeptide of any one of claims 55-97, wherein the polypeptide comprises a Fc peptide comprising a sequence described herein.
99. A method of treating a subject with inflammatory bowel disease, the method comprising administering a polypeptide or antibody of any of claims 1-98 to the subject to treat the inflammatory bowel disease.
100. The method of claim 99, wherein the subject with inflammatory bowel disease has Crohn's disease. 101. The method of claim 99, wherein the subject with inflammatory bowel disease has ulcerative colitis.
102. A method of treating a subject with auto-immune hepatitis, the method comprising administering a polypeptide or antibody of any of claims 1-98 to the subject to treat the auto immune hepatitis.
103. A method of treating primary sclerosing cholangitis the method comprising administering a polypeptide or antibody of any of claims 1-98 to the subject to treat the primary sclerosing cholangitis.
104. A method of treating Type 1 diabetes the method comprising administering a polypeptide or antibody of any of claims 1-98 to the subject to treat the Type 1 diabetes.
105. A method of treating a transplant subject comprising administering a therapeutically effective amount of a polypeptide or antibody of any of claims 1-98 to the subject,
thereby treating a transplant (recipient) subject.
106. A method of treating GVHD in a subject having a transplanted a donor tissue comprising administering a therapeutically effective amount of a polypeptide or antibody of any of claims 1- 98 to the subject.
107. A method of treating a subject having, or at risk, or elevated risk, for having, an autoimmune disorder, comprising administering a therapeutically effective amount of a polypeptide or antibody of any of claims 1-98, thereby treating the subject.
108. A nucleic acid encoding a polypeptide or antibody of any of claims 1-98.
109. A vector comprising the nucleic acid of claim 108. 110. A cell comprising the nucleic acid of claim 108 or the vector of claim 109.
111. A method of making a polypeptide or antibody of any of claims 1-98 comprising culturing a cell of claim 110 to make the polypeptide or antibody of any of claims 1-98.
112. A protein comprising a peptide or set of peptides as provided in Table 6 or Table 7.
113. The protein of claim 112, wherein the protein comprises a set of sequences as set forth in a row of Table 6 or Table 7.
114. A protein comprising:
i) a peptide comprising a sequence of SEQ ID NO: 90, 91, 92, 93, 94, 170, 359, 360,
361, 362, 363, 135, 381, 382, 383, 384, or 385, or any variant of the foregoing;
ii) a peptide comprising a sequence of SEQ ID NOs: 90, 91, 92, 93, 87, and 94, or any variant of any of the foregoing;
iii) a peptide comprising a sequence of SEQ ID NOs: 135, 381, 382, 383, 384, and 385, or any variant of any of the foregoing;
iv) a peptide comprising a sequence of SEQ ID NOs: 359, 170, 360, 361, 362, and 363, or any variant of any of the foregoing;
v) a peptide comprising a sequence of SEQ ID NOs: 90, 91, and 92, or any variant of any of the foregoing;
vi) a peptide comprising a sequence of SEQ ID NOs: 93, 87, and 94, or any variant of any of the foregoing;
vii) a peptide comprising a sequence of SEQ ID NOs: 135, 381, and 382 or any variant of any of the foregoing;
viii) a peptide comprising a sequence of SEQ ID NOs: 383, 384, and 385, or any variant of any of the foregoing;
ix) a peptide comprising a sequence of SEQ ID NOs: 359, 170, and 360, or any variant of any of the foregoing; or
x) a peptide comprising a sequence of SEQ ID NOs: 361, 362, and 363, or any variant of any of the foregoing. 115. A pharmaceutical composition comprising a polypeptide or antibody of any of claims 1- 98 or 112-114.
116. A pharmaceutical composition comprising any peptide comprising a sequence as provided for herein.
</claims>
</document>
